CY1105185T1 - Σταθepα σκευασματα ινσουλινης - Google Patents

Σταθepα σκευασματα ινσουλινης

Info

Publication number
CY1105185T1
CY1105185T1 CY20061101226T CY061101226T CY1105185T1 CY 1105185 T1 CY1105185 T1 CY 1105185T1 CY 20061101226 T CY20061101226 T CY 20061101226T CY 061101226 T CY061101226 T CY 061101226T CY 1105185 T1 CY1105185 T1 CY 1105185T1
Authority
CY
Cyprus
Prior art keywords
statepa
present
insulin preparation
arginine
diabetes
Prior art date
Application number
CY20061101226T
Other languages
English (en)
Inventor
Michael Rosario Defelippis
Michael Allen Dobbins
Bruce Hill Frank
Shun Li
Dawn Marie Rebhun
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP98304661A external-priority patent/EP0884053B1/en
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of CY1105185T1 publication Critical patent/CY1105185T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Η παρούσα εφεύρεση παρέχει ένα σκεύασμα μονομερούς αναλόγου της ινσουλίνης σταθεροποιημένο έναντι της κροκύδωσης, στο οποίο ο παράγοντας ρύθμισης είναι TRIS ή αργινίνη. Τα σταθερά σκευάσματα της παρούσας εφεύρεσης είναι χρήσιμα για την θεραπεία του διαβήτη, και είναι ιδιαίτερα ευνοϊκά για θεραπευτικές αγωγές που απαιτούν μακροχρόνια χημική και φυσική σταθερότητα, όπως τα συστήματα συνεχούς έγχυσης.
CY20061101226T 1997-06-13 2006-08-30 Σταθepα σκευασματα ινσουλινης CY1105185T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5308997P 1997-06-13 1997-06-13
EP98304661A EP0884053B1 (en) 1997-06-13 1998-06-12 Stable insulin formulations

Publications (1)

Publication Number Publication Date
CY1105185T1 true CY1105185T1 (el) 2010-03-03

Family

ID=26151292

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20061101226T CY1105185T1 (el) 1997-06-13 2006-08-30 Σταθepα σκευασματα ινσουλινης

Country Status (4)

Country Link
EP (1) EP1283051B1 (el)
CY (1) CY1105185T1 (el)
DK (1) DK1283051T3 (el)
SI (1) SI0884053T1 (el)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1660531A2 (en) 2003-08-05 2006-05-31 Novo Nordisk A/S Novel insulin derivatives
DK1969004T3 (da) 2005-12-28 2011-11-28 Novo Nordisk As Insulinsammensætninger og metode til at lave en sammensætning
US9034818B2 (en) 2007-06-13 2015-05-19 Novo Nordisk A/S Pharmaceutical formulations comprising an insulin derivative
EP2158927A1 (en) 2008-08-25 2010-03-03 Debiotech S.A. Drug delivery device with a module for preventing fibrillation downstream of its reservoir
CA2738615A1 (en) 2008-10-30 2010-05-06 Novo Nordisk A/S Treating diabetes melitus using insulin injections with less than daily injection frequency
CN102470165B (zh) * 2009-06-26 2014-12-24 诺沃-诺迪斯克有限公司 包含胰岛素、烟酰胺和氨基酸的制剂
BR112013010345A2 (pt) 2010-10-27 2017-07-25 Novo Nordisk As tratamento de diabetes melitus usando as injeções de insulina administradas com intervalos de variação da injeção
AU2011343360A1 (en) * 2010-12-14 2013-06-06 Novo Nordisk A/S Preparation comprising insulin, nicotinamide and an amino acid
WO2012080320A1 (en) * 2010-12-14 2012-06-21 Novo Nordisk A/S Fast-acting insulin in combination with long-acting insulin
WO2013186138A1 (en) * 2012-06-14 2013-12-19 Novo Nordisk A/S Preparation comprising insulin, nicotinamide and arginine
US10137172B2 (en) 2013-04-30 2018-11-27 Novo Nordisk A/S Administration regime
GB201607918D0 (en) 2016-05-06 2016-06-22 Arecor Ltd Novel formulations
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5767548A (en) * 1980-10-14 1982-04-24 Shionogi & Co Ltd Insulin analog and its preparation
FI78616C (fi) * 1982-02-05 1989-09-11 Novo Industri As Foerfarande foer framstaellning av en foer infusionsaendamaol avsedd stabiliserad insulinloesning, som har en foerhoejd zinkhalt.
DK179286D0 (da) * 1986-04-18 1986-04-18 Nordisk Gentofte Insulinpraeparat
US5461031A (en) * 1994-06-16 1995-10-24 Eli Lilly And Company Monomeric insulin analog formulations
YU18596A (sh) * 1995-03-31 1998-07-10 Eli Lilly And Company Analogne formulacije monomernog insulina

Also Published As

Publication number Publication date
EP1283051A1 (en) 2003-02-12
SI0884053T1 (en) 2003-02-28
DK1283051T3 (da) 2006-10-16
EP1283051B1 (en) 2006-06-14

Similar Documents

Publication Publication Date Title
CY1105185T1 (el) Σταθepα σκευασματα ινσουλινης
TR199903036T2 (xx) Kararl� insulin form�lasyonlar�.
CY1111504T1 (el) Αζαδικυκλοαλκανια ως ρυθμιστες του ccr5
PT944398E (pt) Sistema de entrega percutanea
NO20014415D0 (no) Medisinske preparater til behandling av <alfa>-galaktosidase- A-defisiens
DK1172114T3 (da) Stabile koncentrerede insulinpræparater til pulmonær indgivelse
DE60327994D1 (de) Ansamycine mit verbesserten pharmakologischen und biologischen eigenschaften
FI962154A0 (fi) Koostumus terapeuttisten tuotteiden in vivo valmistusta varten
EP1196444B8 (en) Exendin-4 conjugates and their medical use
TR200200938T2 (tr) CCR5 modülatörleri olarak piperidinler
DK0693924T3 (da) Fremgangsmåde til (in vivo)-levering af biologiske materialer og sammensætninger, der er egnede dertil
DE69332856D1 (de) Haarnadelförmiges ribozym
BR9709823A (pt) Amidas de piridil alqueno-e priridil alquino-ácido como citostáticos e imuno-supressores
DE60214173D1 (de) Negativ geladenes amphiphiles blockcopolymer als arzneistoffträger und komplex davon mit postitiv geladenem arzneistoff
DK0921812T3 (da) Insulinpræparater, som indeholder NaCi
DE69725825D1 (de) 5-HT1F-Agonisten
ATE495739T1 (de) Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa
HUP0000664A2 (hu) Azinil-oxi- és fenoxi-diaril-karbonsavszármazékok, eljárás előállításukra és alkalmazásuk gyógyszerkészítmények előállítására
DE59407457D1 (de) Blockierung der anlagerung von keimen an menschliche zellen
DE60220796D1 (de) Positiv geladenes amphiphiles blockcopolymer als arzneistoffträger und komplex davon mit negativ geladenem arzneistoff
NO331082B1 (no) Formulering av kahalalid F, sett omfattende en slik formulering, samt rekonstituert losning derav og anvendelse av en fortynnet rekonstituert losning til fremstilling av et medikament for behandling av kreft
NO952336L (no) Insulin analoger
DE60317565D1 (de) Pharmazeutische zusammensetzungen mit insulin und insulin-hexamer-liganden
TR199802044T2 (xx) Yeni karbon asidi t�revleri, �retilmeleri ve kullan�mlar�.
DK188680A (da) Fremgangsmaade til fremstilling af 6-substituerede 11-alkylenmorphantridiner